USFDA Concludes Inspection at Cohance Lifesciences Formulation Facility with Four Observations
Cohance Lifesciences Ltd 路 Others (Uncategorized) 路 05 Sept 2026, 5:59 am
USFDA Concludes Inspection at Cohance Lifesciences Formulation Facility with Four Observations The USFDA completed an inspection of Cohance Lifesciences Limited's formulation (FDF) plant located at Shamshabad, Telangana, conducted from 27th Aug'26 to 4th Sep'26. The regulatory audit concluded with the issuance of a Form FDA 483 containing four observations. The company confirmed it has initiated appropriate corrective and preventive actions (CAPA) and will submit its formal response to the regulatory agency within the stipulated timeline.
Original exchange filing (PDF)
More announcements from Cohance Lifesciences Ltd
- The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasti Property and Equity Holdings .... 路 12 Nov 2026
- The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasub Property Holdings LLP & Others 路 12 Nov 2026
- Investors Meet 路 11 Nov 2026
- Transcript of Con call 路 11 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasub Property Holdings LLP & Others 路 11 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasti Property and Equity Holdings Pvt Ltd & Others 路 11 Nov 2026
- Investor Presentation 路 07 Nov 2026
- Update on USFDA inspection at Pashamylaram Manufacturing facility. 路 07 Nov 2026
